Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 18–19

18 Medicinal products by Interaction Recommendations concerning co- therapeutic area administration ANTINEOPLASTICS AND IMMUNOSUPRESSANTS Antineoplastics Apalutamide The mechanism of interaction is CYP3A4 Co-administration with REYATAZ induction by apalutamide and CYP3A4 (with or without ritonavir) is inhibition by atazanavir/ritonavir. contraindicated due to the potential for decreased atazanavir and ritonavir plasma concentration with subsequent loss of virologic response and possible resistance to the class of protease inhibitors (see section 4.3). In addition, serum concentrations of apalutamide may be increased when coadministered with atazanavir/ritonavir, resulting in the potential for serious adverse events including seizure. Encorafenib The mechanism of interaction is CYP3A4 Co-administration of encorafenib inhibition by atazanavir and/or ritonavir. with REYATAZ (with or without ritonavir) is contraindicated due to the potential for loss of virologic response, development of resistance, increase in encorafenib plasma concentration and subsequent risk of serious adverse events such as QT interval prolongation (see section 4.3). Ivosidenib The mechanism of interaction is CYP3A4 Co-administration of ivosidenib inhibition by atazanavir and/or ritonavir. with REYATAZ (with or without ritonavir) is contraindicated due to potential for loss of virologic response, development of resistance, increase in ivosidenib plasma concentration and subsequent risk of serious adverse events such as QT interval prolongation (see section 4.3). Irinotecan Atazanavir inhibits UGT and may interfere If REYATAZ is co-administered with the metabolism of irinotecan, with irinotecan, patients should be resulting in increased irinotecan toxicities. closely monitored for adverse events related to irinotecan. Immunosuppressants Cyclosporin Concentrations of these More frequent therapeutic Tacrolimus immunosuppressants may be increased concentration monitoring of these Sirolimus when co-administered with REYATAZ medicinal products is recommended due to CYP3A4 inhibition. until plasma levels have been stabilised. CARDIOVASCULAR AGENTS Antiarrhythmics Amiodarone, Concentrations of these antiarrhythmics Caution is warranted and Systemic lidocaine, may be increased when co-administered therapeutic concentration Quinidine with REYATAZ. The mechanism of monitoring is recommended when amiodarone or systemic available. The concomitant use of lidocaine/atazanavir interaction is CYP3A quinidine is contraindicated inhibition. Quinidine has a narrow (see section 4.3). therapeutic window and is contraindicated due to potential inhibition of CYP3A by REYATAZ.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) lidocaine (HOS-108866) apalutamide (HOS-086212) quinidine (HOS-085593) encorafenib (HOS-086222) tacrolimus (HOS-085202) ivosidenib (HOS-112046) sirolimus (HOS-085172) ritonavir (HOS-084521) amiodarone (HOS-085596) irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage c9ed9e0270f64ec8df603d7aa8f424ad74b96d960cc137508e6d9081efdb4558 · Zeichen 45345–51108 im Abschnitt

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 54–55

HOS-112192 · Präparat HOS-093615

54 Medicinal products by Interaction Recommendations therapeutic area concerning co-administration Ivosidenib The mechanism of interaction is CYP3A4 Co-administration of inhibition by atazanavir and/or ritonavir. ivosidenib with REYATAZ (with or without ritonavir) is contraindicated due to potential for loss of virologic response, development of resistance, increase in ivosidenib plasma concentration and subsequent risk of serious adverse events such as QT interval prolongation (see section 4.3). Irinotecan Atazanavir inhibits UGT and may interfere If REYATAZ is co- with the metabolism of irinotecan, resulting administered with irinotecan, in increased irinotecan toxicities. patients should be closely monitored for adverse events related to irinotecan. Immunosuppressants Cyclosporin Concentrations of these More frequent therapeutic Tacrolimus immunosuppressants may be increased concentration monitoring of Sirolimus when co-administered with REYATAZ due these medicinal products is to CYP3A4 inhibition. recommended until plasma levels have been stabilised. CARDIOVASCULAR AGENTS Antiarrhythmics Amiodarone, Concentrations of these antiarrhythmics Caution is warranted and Systemic lidocaine, may be increased when co-administered therapeutic concentration Quinidine with REYATAZ. The mechanism of monitoring is recommended amiodarone or systemic when available. The lidocaine/atazanavir interaction is CYP3A concomitant use of quinidine is inhibition. Quinidine has a narrow contraindicated (see therapeutic window and is contraindicated section 4.3). due to potential inhibition of CYP3A by REYATAZ. Calcium channel blockers Bepridil REYATAZ should not be used in Co-administration with combination with medicinal products that bepridil is contraindicated (see are substrates of CYP3A4 and have a section 4.3) narrow therapeutic index. Diltiazem 180 mg once daily Diltiazem AUC: ↑125% (↑109% ↑141%) An initial dose reduction of (atazanavir 400 mg once daily) Diltiazem Cmax: ↑98% (↑78% ↑119%) diltiazem by 50% is Diltiazem Cmin: ↑142% (↑114% ↑173%) recommended, with subsequent titration as needed and ECG Desacetyl-diltiazem AUC: ↑165% (↑145% monitoring. ↑187%) Desacetyl-diltiazem Cmax: ↑172% (↑144% ↑203%) Desacetyl-diltiazem Cmin: ↑121% (↑102% ↑142%)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) lidocaine (HOS-108866) bepridil (HOS-085612) quinidine (HOS-085593) calcium (HOS-085615) tacrolimus (HOS-085202) ivosidenib (HOS-112046) sirolimus (HOS-085172) ritonavir (HOS-084521) amiodarone (HOS-085596) irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8e30f6119b7915e33c652e423a799b6a4590263851081846f12e942eec018b80 · Zeichen 49648–54131 im Abschnitt

Wechselwirkungen · Erbitux

Erbitux 5 mg/mL solution for infusion · Abschnitt 4.5 · PDF-Seite 8

HOS-113168 · Präparat HOS-093871

A formal interaction study showed that the pharmacokinetic characteristics of cetuximab remain unaltered after co-administration of a single dose of irinotecan (350 mg/m2 body surface area). Similarly, the pharmacokinetics of irinotecan were unchanged when cetuximab was co-administered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-15T11:55:00Z · SHA-256 073f5effd93351048ad74afee3f940b1c0ad5d24722452304a7b761a65e30f20 · Passage 8d9ed510eaf4bd98b5d310c62fd00d08d0aedcd088a9dbf08d1952ea2792d8ff · Zeichen 689–976 im Abschnitt

Wechselwirkungen · Avastin

Avastin 25 mg/ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9

HOS-113531 · Präparat HOS-093945

Effect of bevacizumab on the pharmacokinetics of other antineoplastic agents No clinically relevant interaction of bevacizumab was observed on the pharmacokinetics of co- administered interferon alfa 2a, erlotinib (and its active metabolite OSI-420), or the chemotherapies irinotecan (and its active metabolite SN38), capecitabine, oxaliplatin (as determined by measurement of free and total platinum), and cisplatin. Conclusions on the impact of bevacizumab on gemcitabine pharmacokinetics cannot be drawn.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): platinum (HOS-086055) gemcitabine (HOS-113530) cisplatin (HOS-086022) erlotinib (HOS-113527) capecitabine (HOS-090904) oxaliplatin (HOS-091432) irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-01-27T12:02:00Z · SHA-256 66d06bf8e8d4853783377bc4046bd6b4b0e313cc348c230743646f93a9381bb1 · Passage 1745c8059a824a1b14465bffa2bc20de6cced92c506d2029e0bcf7b8fcd615af · Zeichen 585–1092 im Abschnitt

Wechselwirkungen · Nexavar

Nexavar 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-115764 · Präparat HOS-094353

In clinical studies sorafenib has been administered with a variety of other anti-neoplastic agents at their commonly used dosing regimens including gemcitabine, cisplatin, oxaliplatin, paclitaxel, carboplatin, capecitabine, doxorubicin, irinotecan, docetaxel and cyclophosphamide. Sorafenib had no clinically relevant effect on the pharmacokinetics of gemcitabine, cisplatin, carboplatin, oxaliplatin or cyclophosphamide.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): gemcitabine (HOS-113530) cisplatin (HOS-086022) docetaxel (HOS-084505) carboplatin (HOS-084540) capecitabine (HOS-090904) cyclophosphamide (HOS-084539) oxaliplatin (HOS-091432) paclitaxel (HOS-087959) doxorubicin (HOS-084538) irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-03-28T11:40:00Z · SHA-256 4561f7f7d54908430c2d44ab3a6a7808fbf136793e601e405c6fd3f8791d1b27 · Passage 03ec0414f3769c1553ef113f9e65bc3c47eaf9a5ef56f39d1288ca393a0c8149 · Zeichen 2815–3236 im Abschnitt

Wechselwirkungen · Nexavar

Nexavar 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8

HOS-115779 · Präparat HOS-094353

Doxorubicin/Irinotecan

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxorubicin (HOS-084538) irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-03-28T11:40:00Z · SHA-256 4561f7f7d54908430c2d44ab3a6a7808fbf136793e601e405c6fd3f8791d1b27 · Passage bf7bec4055f07f009f79e8e9d3ad6d2234607f65fd963b9bbd54eea6138898d1 · Zeichen 4886–4908 im Abschnitt

Wechselwirkungen · Nexavar

Nexavar 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8

HOS-115780 · Präparat HOS-094353

Concomitant treatment with sorafenib resulted in a 21 % increase in the AUC of doxorubicin. When administered with irinotecan, whose active metabolite SN-38 is further metabolised by the UGT1A1 pathway, there was a 67 - 120 % increase in the AUC of SN-38 and a 26 - 42 % increase in the AUC of irinotecan. The clinical significance of these findings is unknown (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxorubicin (HOS-084538) irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-03-28T11:40:00Z · SHA-256 4561f7f7d54908430c2d44ab3a6a7808fbf136793e601e405c6fd3f8791d1b27 · Passage bb631d3ccea5d1c420dcc2c0d1fdb2d054790991eb4a2f63bc1543642c6753f0 · Zeichen 4910–5289 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 19

HOS-116392 · Präparat HOS-094447

Everolimus Concomitant use of everolimus or Irinotecan irinotecan and boosted PREZISTA is not recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): everolimus (HOS-086310) irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 9129a3e633996192f47cda0e9e8d18163404eaa6ca0c83c5cfc19495421a65a5 · Zeichen 51636–51946 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61

HOS-116526 · Präparat HOS-094447

Everolimus Concomitant use of everolimus or Irinotecan irinotecan and PREZISTA co-administered with low dose ritonavir is not recommended. ANTIPSYCHOTICS/NEUROLEPTICS Quetiapine Not studied. PREZISTA is expected to Concomitant administration of increase these antipsychotic plasma PREZISTA with low dose concentrations. ritonavir and quetiapine is (CYP3A inhibition) contraindicated as it may increase quetiapine-related toxicity. Increased concentrations of quetiapine may lead to coma (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) lead (HOS-085592) everolimus (HOS-086310) ritonavir (HOS-084521) irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 18aed816dca48176025dcb58213f9af8485c4e13d8d817997ae2993ed50f29ba · Zeichen 41969–43232 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 101

HOS-116616 · Präparat HOS-094447

Everolimus Concomitant use of everolimus or Irinotecan irinotecan and boosted PREZISTA is not recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): everolimus (HOS-086310) irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 9129a3e633996192f47cda0e9e8d18163404eaa6ca0c83c5cfc19495421a65a5 · Zeichen 51108–51418 im Abschnitt

Wechselwirkungen · Vectibix

Vectibix 20 mg/mL concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 6

HOS-117393 · Präparat HOS-094601

Data from an interaction study involving Vectibix and irinotecan in patients with mCRC indicated that the pharmacokinetics of irinotecan and its active metabolite, SN-38, are not altered when the medicinal products are co-administered. Results from a cross-study comparison indicated that irinotecan-containing regimens (IFL or FOLFIRI) have no effect on the pharmacokinetics of panitumumab.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-05-07T10:43:00Z · SHA-256 623c963b5fb57ad899208d5b3acaf4f91d25565ad9b26d6ae5a16bcb53a34569 · Passage a577697dfe653f69eb3b4c60b3a3dd57204a06598a3a5c48ef402cfbbd3d6e81 · Zeichen 0–391 im Abschnitt

Wechselwirkungen · Tyverb

Tyverb 250 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-208930 · Präparat HOS-154213

Co-administration of Tyverb with irinotecan (when administered as part of the FOLFIRI regimen) resulted in an approximate 40% increase in the AUC of SN-38, the active metabolite of irinotecan. The precise mechanism of this interaction is unknown, but it is assumed to be due to inhibition of one or more transport proteins by lapatinib. Adverse reactions should be carefully monitored if Tyverb is co-administered with irinotecan, and a reduction in the dose of irinotecan should be considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-01-06T15:40:00Z · SHA-256 cc5bd96641c0b3f4003ec76839196782d898a5b2fc432b1735c84b65f7171b92 · Passage 06f46ca7b32018c4ea96939e10208f7148f1ea3817f7ea712f28cc6106f69039 · Zeichen 3139–3633 im Abschnitt

Wechselwirkungen · Votrient

Votrient 200 mg film-coated tablets Votrient 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10

HOS-122575 · Präparat HOS-095539

9 Pazopanib is an inhibitor of the uridine diphosphoglucuronosyl-transferase 1A1 (UGT1A1) enzyme in vitro. The active metabolite of irinotecan, SN-38, is a substrate for OATP1B1 and UGT1A1. Co-administration of pazopanib 400 mg once daily with cetuximab 250 mg/m2 and irinotecan 150 mg/m2 resulted in an approximately 20% increase in systemic exposure to SN-38. Pazopanib may have a greater impact on SN-38 disposition in subjects with the UGT1A1*28 polymorphism relative to subjects with the wild-type allele. However, the UGT1A1 genotype was not always predictive of the effect of pazopanib on SN-38 disposition. Care should be taken when pazopanib is co-administered with substrates of UGT1A1.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cetuximab (HOS-113159) uridine (HOS-085192) irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-10-28T11:24:00Z · SHA-256 38e00132fe316301c56a9c9a4f9247483c54b55dd743bedaab120a272380aaff · Passage bdc4788db7d4a842ef79ff65f498218fa16b482e4c354b42926c4ef8deaddeea · Zeichen 5358–6055 im Abschnitt

Gegenanzeigen · Teysuno

Teysuno 15 mg/4.35 mg/11.8 mg hard capsules · Abschnitt 4.3 · PDF-Seite 8

HOS-123696 · Präparat HOS-095721

• Contraindications for cisplatin; oxaliplatin, irinotecan and bevacizumab refer to the corresponding SmPCs.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisplatin (HOS-086022) oxaliplatin (HOS-091432) bevacizumab (HOS-091433) irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-10-30T14:44:00Z · SHA-256 d9fd4d001c3fc80cad8997ad588ff4e933bbc1b0d72de30b71e72b1dd2b35ec9 · Passage 5a3cc7e2ae22f95cae3a280f2f4d4a1b94a35a9e2740d0b3b65cdbc91112f6f3 · Zeichen 713–831 im Abschnitt

Gegenanzeigen · Teysuno

Teysuno 20 mg/5.8 mg/15.8 mg hard capsules · Abschnitt 4.3 · PDF-Seite 33

HOS-123762 · Präparat HOS-095721

• Contraindications for cisplatin, oxaliplatin, irinotecan and bevacizumab; refer to the corresponding SmPCs.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisplatin (HOS-086022) oxaliplatin (HOS-091432) bevacizumab (HOS-091433) irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-10-30T14:44:00Z · SHA-256 d9fd4d001c3fc80cad8997ad588ff4e933bbc1b0d72de30b71e72b1dd2b35ec9 · Passage 2d61d0a3b7299ff30ee095fa0faedb878a39f2dc4cc3015201e80cf01fe48d0d · Zeichen 721–840 im Abschnitt

Wechselwirkungen · Xalkori

XALKORI 200 mg hard capsules XALKORI 250 mg hard capsules XALKORI 20 mg granules in capsules for opening XALKORI 50 mg granules in capsules for opening XALKORI 150 mg granules in capsules for opening · Abschnitt 4.5 · PDF-Seite 16

HOS-126284 · Präparat HOS-096239

In vitro studies indicated that crizotinib is a weak inhibitor of uridine diphosphate glucuronosyltransferase (UGT)1A1 and UGT2B7. Therefore, crizotinib may have the potential to increase plasma concentrations of coadministered medicinal products that are metabolised predominantly by UGT1A1 (e.g., raltegravir, irinotecan) or UGT2B7 (e.g., morphine, naloxone).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): morphine (HOS-086053) naloxone (HOS-109490) raltegravir (HOS-086187) uridine (HOS-085192) irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-09-17T11:44:00Z · SHA-256 ef70dd9e8f617f709767e5bd4c7044eb23893a7ac40281434ebfa2fb8fb4e3d5 · Passage f7028ed14c6551ed5f1262b416ee82afd27a4ab519d19452d601e7cbc808952b · Zeichen 5362–5723 im Abschnitt

Gegenanzeigen · Zaltrap

ZALTRAP 25 mg/ml concentrate for solution for infusion · Abschnitt 4.3 · PDF-Seite 5

HOS-215762 · Präparat HOS-155534

For contraindications related to FOLFIRI components (irinotecan, 5-FU, and folinic acid), refer to the current respective summary of product characteristics.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-08-29T14:23:00Z · SHA-256 5b4c1b4848635140cdb6155c414b72c6acf77bc314124cac5763c972a8858b1a · Passage 289daf702d9ffb39b56cdc1be38d9de34c05da51a8502c119e66bfc9f8ccef58 · Zeichen 176–333 im Abschnitt

Wechselwirkungen · Stivarga

Stivarga 40 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 8

HOS-127092 · Präparat HOS-096369

UGT1A1 and UGT1A9 substrates In vitro data indicate that regorafenib as well as its active metabolite M-2 inhibit glucuronidation mediated by UGT1A1 and UGT1A9 whereas M-5 only inhibits UGT1A1 at concentrations which are achieved in vivo at steady state. Administration of regorafenib with a 5-day break prior to administration of irinotecan resulted in an increase of approximately 44% in AUC of SN-38, a substrate of UGT1A1 and an active metabolite of irinotecan. An increase in AUC of irinotecan of approximately 28% was also observed. This indicates that co-administration of regorafenib may increase systemic exposure to UGT1A1 and UGT1A9 substrates.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): irinotecan (HOS-112102)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-03-24T12:26:00Z · SHA-256 188477d5802aa3c29bbcc6435c9e581d56ccf3178a537b51e23d7bce8cf4f8be · Passage 2027cf55300aa6dd931fb41dbef416e5f3f89b2c7af7df6071d8ec94fa4c8ca5 · Zeichen 1776–2431 im Abschnitt

Wechselwirkungen · Cresemba

CRESEMBA 200 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9–10

HOS-128908 · Präparat HOS-096645

(Mechanism unknown) Other anticancer agents Not studied. No isavuconazole dose (daunorubicin, doxorubicin, Daunorubicin, doxorubicin, adjustment necessary. imatinib, irinotecan, lapatinib, imatinib, irinotecan, lapatinib, Daunorubicin, doxorubicin, mitoxantrone, topotecan) mitoxantrone, topotecan imatinib, irinotecan, lapatinib, (BCRP substrates) concentrations may increase. mitoxantrone or topotecan: careful monitoring for any (BCRP inhibition) occurrence of drug toxicity, and dose reduction if required. Antiemetics Aprepitant Not studied. Co-administration should be (mild CYP3A4/5 inducer) Isavuconazole concentrations may avoided unless the potential decrease. benefit is considered to outweigh the risk. (CYP3A4/5 induction) Antidiabetics Metformin Metformin: No isavuconazole dose (OCT1, OCT2 and MATE1 AUCinf: ↑ 52% adjustment necessary. substrate) Cmax: ↑ 23% Metformin: dose reduction may be required. (OCT2 inhibition) Repaglinide Repaglinide: No isavuconazole dose (CYP2C8 and OATP1B1 AUCinf: ↓ 8% adjustment necessary. substrate) Cmax: ↓ 14% Repaglinide: no dose adjustment required. Pioglitazone Not studied. Co-administration should be (mild CYP3A4/5 inducer) avoided unless the potential 9 Isavuconazole concentrations may benefit is considered to outweigh decrease. the risk.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daunorubicin (HOS-089674) aprepitant (HOS-112506) imatinib (HOS-110212) lapatinib (HOS-122565) pioglitazone (HOS-089663) mitoxantrone (HOS-124775) topotecan (HOS-086047) doxorubicin (HOS-084538) irinotecan (HOS-112102) repaglinide (HOS-086935) metformin (HOS-091032)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage 854a91e973c77b9e297df129810c589fef8306f228064f2fd1d019fbd0b296bc · Zeichen 11990–14467 im Abschnitt

Wechselwirkungen · Cresemba

CRESEMBA 40 mg hard capsules CRESEMBA 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 32

HOS-128988 · Präparat HOS-096645

(Mechanism unknown) Other anticancer agents Not studied. No isavuconazole dose (daunorubicin, doxorubicin, Daunorubicin, doxorubicin, adjustment necessary. imatinib, irinotecan, lapatinib, imatinib, irinotecan, lapatinib, Daunorubicin, doxorubicin, mitoxantrone, topotecan) mitoxantrone, topotecan imatinib, irinotecan, lapatinib, (BCRP substrates) concentrations may increase. mitoxantrone or topotecan: careful monitoring for any (BCRP inhibition) occurrence of drug toxicity, and dose reduction if required. Antiemetics Aprepitant Not studied. Co-administration should be (mild CYP3A4/5 inducer) Isavuconazole concentrations may avoided unless the potential decrease. benefit is considered to outweigh the risk. (CYP3A4/5 induction) Antidiabetics Metformin Metformin: No isavuconazole dose (OCT1, OCT2 and MATE1 AUCinf: ↑ 52% adjustment necessary. substrate) Cmax: ↑ 23% Metformin: dose reduction may be required. (OCT2 inhibition) Repaglinide Repaglinide: No isavuconazole dose (CYP2C8 and OATP1B1 AUCinf: ↓ 8% adjustment necessary. substrate) Cmax: ↓ 14% Repaglinide: no dose adjustment required. Pioglitazone Not studied. Co-administration should be (mild CYP3A4/5 inducer) Isavuconazole concentrations may avoided unless the potential decrease. benefit is considered to outweigh the risk. (CYP3A4/5 induction) Anticoagulants Dabigatran etexilate Not studied. No isavuconazole dose (P-gp substrate) Dabigatran etexilate concentrations adjustment necessary. may increase. Dabigatran etexilate has a narrow therapeutic index and should be (P-gp inhibition). monitored, and dose reduction if required. Warfarin S-warfarin No isavuconazole dose (CYP2C9 substrate) AUCinf: ↑ 11% adjustment necessary. Cmax: ↓ 12% Warfarin: no dose adjustment R-warfarin required. AUCinf: ↑ 20% Cmax: ↓ 7% Antiretroviral agents Lopinavir 400 mg / Ritonavir Lopinavir: No isavuconazole dose 100 mg AUCtau: ↓ 27% adjustment necessary; caution is (CYP3A4/5 strong inhibitors Cmax: ↓ 23% advised as adverse drug reactions and substrates) Cmin, ss: ↓ 16%a) may increase. Ritonavir: AUCtau: ↓ 31% Lopinavir/ritonavir: no dose Cmax: ↓ 33% adjustment for lopinavir 400 mg /

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daunorubicin (HOS-089674) lopinavir (HOS-086269) aprepitant (HOS-112506) imatinib (HOS-110212) lapatinib (HOS-122565) pioglitazone (HOS-089663) mitoxantrone (HOS-124775) ritonavir (HOS-084521) topotecan (HOS-086047) doxorubicin (HOS-084538) irinotecan (HOS-112102) dabigatran etexilate (HOS-086233) warfarin (HOS-085950) repaglinide (HOS-086935) metformin (HOS-091032)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage 850ab84615b3abfe437182a0864ac0bf00ab067f02f0d89de60b13f59802225e · Zeichen 12228–16452 im Abschnitt

Quellenpassagen (42)

Wechselwirkungen · Reyataz

Wechselwirkungen · Reyataz

Wechselwirkungen · Erbitux

Wechselwirkungen · Avastin

Wechselwirkungen · Nexavar

Wechselwirkungen · Nexavar

Wechselwirkungen · Nexavar

Wechselwirkungen · Prezista

Wechselwirkungen · Prezista

Wechselwirkungen · Prezista

Wechselwirkungen · Vectibix

Wechselwirkungen · Tyverb

Wechselwirkungen · Votrient

Gegenanzeigen · Teysuno

Gegenanzeigen · Teysuno

Wechselwirkungen · Xalkori

Gegenanzeigen · Zaltrap

Wechselwirkungen · Stivarga

Wechselwirkungen · Cresemba

Wechselwirkungen · Cresemba